-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Great West Life Assurance Co. Can Invests $470,000 in ITeos Therapeutics, Inc. (NASDAQ:ITOS)
Great West Life Assurance Co. Can Invests $470,000 in ITeos Therapeutics, Inc. (NASDAQ:ITOS)
Great West Life Assurance Co. Can bought a new stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) during the third quarter, according to its most recent filing with the SEC. The firm bought 24,710 shares of the company's stock, valued at approximately $470,000. Great West Life Assurance Co. Can owned about 0.07% of iTeos Therapeutics at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Prairiewood Capital LLC acquired a new position in iTeos Therapeutics in the 3rd quarter valued at $615,000. Alps Advisors Inc. acquired a new position in iTeos Therapeutics in the 2nd quarter valued at $434,000. Rafferty Asset Management LLC grew its stake in iTeos Therapeutics by 2.1% in the 2nd quarter. Rafferty Asset Management LLC now owns 99,368 shares of the company's stock valued at $2,047,000 after buying an additional 2,067 shares during the last quarter. Principal Financial Group Inc. grew its stake in iTeos Therapeutics by 22.7% in the 2nd quarter. Principal Financial Group Inc. now owns 167,750 shares of the company's stock valued at $3,455,000 after buying an additional 31,004 shares during the last quarter. Finally, Virtus ETF Advisers LLC grew its stake in iTeos Therapeutics by 39.1% in the 2nd quarter. Virtus ETF Advisers LLC now owns 5,790 shares of the company's stock valued at $119,000 after buying an additional 1,629 shares during the last quarter.
Get iTeos Therapeutics alerts:iTeos Therapeutics Trading Up 2.3 %
NASDAQ:ITOS opened at $20.77 on Friday. iTeos Therapeutics, Inc. has a 1 year low of $16.21 and a 1 year high of $37.88. The firm's fifty day simple moving average is $19.88 and its 200 day simple moving average is $20.92. The firm has a market capitalization of $739.00 million, a PE ratio of 3.02 and a beta of 1.37.
iTeos Therapeutics (NASDAQ:ITOS – Get Rating) last posted its quarterly earnings results on Thursday, November 10th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.04). The company had revenue of $19.49 million during the quarter, compared to analyst estimates of $42.05 million. iTeos Therapeutics had a return on equity of 42.62% and a net margin of 57.48%. As a group, analysts anticipate that iTeos Therapeutics, Inc. will post 2.85 EPS for the current fiscal year.iTeos Therapeutics Company Profile
(Get Rating)
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
See Also
- Get a free copy of the StockNews.com research report on iTeos Therapeutics (ITOS)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
Want to see what other hedge funds are holding ITOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating).
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Great West Life Assurance Co. Can bought a new stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) during the third quarter, according to its most recent filing with the SEC. The firm bought 24,710 shares of the company's stock, valued at approximately $470,000. Great West Life Assurance Co. Can owned about 0.07% of iTeos Therapeutics at the end of the most recent quarter.
大西部人寿保险公司根据iTeos Therapeutics, Inc.（纳斯达克股票代码：ITOS — Get Rating）的最新文件，坎在第三季度购买了iTeos Therapeutics, Inc.（纳斯达克股票代码：ITOS该公司购买了该公司24,710股股票，价值约47万美元。大西部人寿保险公司在最近一个季度末，Can拥有iTeos Therapeutics约0.07％的股份。
Other hedge funds and other institutional investors have also bought and sold shares of the company. Prairiewood Capital LLC acquired a new position in iTeos Therapeutics in the 3rd quarter valued at $615,000. Alps Advisors Inc. acquired a new position in iTeos Therapeutics in the 2nd quarter valued at $434,000. Rafferty Asset Management LLC grew its stake in iTeos Therapeutics by 2.1% in the 2nd quarter. Rafferty Asset Management LLC now owns 99,368 shares of the company's stock valued at $2,047,000 after buying an additional 2,067 shares during the last quarter. Principal Financial Group Inc. grew its stake in iTeos Therapeutics by 22.7% in the 2nd quarter. Principal Financial Group Inc. now owns 167,750 shares of the company's stock valued at $3,455,000 after buying an additional 31,004 shares during the last quarter. Finally, Virtus ETF Advisers LLC grew its stake in iTeos Therapeutics by 39.1% in the 2nd quarter. Virtus ETF Advisers LLC now owns 5,790 shares of the company's stock valued at $119,000 after buying an additional 1,629 shares during the last quarter.
其他对冲基金和其他机构投资者也买入和卖出了该公司的股票。Prairiewood Capital LLC在第三季度收购了iTeos Therapeutics的新职位，价值61.5万美元。Alps Advisors Inc.在第二季度收购了iTeOS Therapeutics的新职位，价值43.4万美元。拉弗蒂资产管理有限责任公司在第二季度将其在iTeOS Therapeutics的股份增加了2.1％。Rafferty Asset Management LLC在上个季度又购买了2,067股股票后，现在拥有该公司99,368股股票，价值为2,047,000美元。信安金融集团公司在第二季度将其在iTeOS Therapeutics的股份增加了22.7％。Principal Financial Group Inc.在上个季度又购买了31,004股股票后，现在拥有该公司167,750股股票，价值3,455,000美元。最后，Virtus ETF Advisors LLC在第二季度将其在iTeOS Therapeutics的股份增加了39.1％。Virtus ETF Advisors LLC在上个季度又购买了1,629股股票后，现在拥有该公司5,790股股票，价值11.9万美元。
iTeos Therapeutics Trading Up 2.3 %
iTeos Therapeutics 交易价格上涨
NASDAQ:ITOS opened at $20.77 on Friday. iTeos Therapeutics, Inc. has a 1 year low of $16.21 and a 1 year high of $37.88. The firm's fifty day simple moving average is $19.88 and its 200 day simple moving average is $20.92. The firm has a market capitalization of $739.00 million, a PE ratio of 3.02 and a beta of 1.37.
纳斯达克股票代码：ITOS周五开盘价为20.77美元。iTeos Therapeutics, Inc.创下1年低点16.21美元，创1年高点37.88美元。该公司的五十天简单移动平均线为19.88美元，其200天简单移动平均线为20.92美元。该公司的市值为7.39亿美元，市盈率为3.02，beta为1.37。
iTeos Therapeutics Company Profile
iTeos Therapeutic
(Get Rating)
（获取评分）
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Iteos Therapeutics, Inc是一家临床阶段的生物制药公司，从事患者免疫肿瘤疗法的发现和开发。该公司的产品线包括 inupadenant，一种正在进行第 2 期临床试验的腺苷 A2AR 拮抗剂的小分子拮抗剂；以及 EOS-448，一种具有 Ig 和 ITIM 结构域的 TIGIT 或 T 细胞免疫受体的拮抗剂，正处于 1/2 期临床试验，用于与 Fc 伽玛受体或 Fc？R 激活树突状细胞和巨噬细胞，促进抗体依赖性细胞毒性或 ADCC 活性。
See Also
另见
- Get a free copy of the StockNews.com research report on iTeos Therapeutics (ITOS)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
- 免费获取 StockNews.com 关于 iTEOS Therapeutics (ITOS) 的研究报告的副本
- 细价股值得吗？你应该投资细价股吗？
- Zimmer Biomet的收益超过预期，增长可能会被定价
- 人工智能软件制造商 EPAM 拥有最大的科技板块涨势
- 在收益大幅下滑之后，福特股票将向前发展
- 内部人士和机构在全球范围内收购金刚狼
Want to see what other hedge funds are holding ITOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating).
想看看还有哪些对冲基金持有ITOS吗？ 访问Holdingschannel.com，获取iTeOS Therapeutics, Inc.（纳斯达克股票代码：ITOS — 获取评级）的最新13F文件和内幕交易。
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 iTeOS Therapeutics 每日的新闻和评 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收iTeOS Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧